TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Opthea ( (AU:OPT) ) is now available.
Opthea Limited has announced the application for the quotation of 136,661,003 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of a settlement for a development funding agreement. This move is expected to enhance Opthea’s financial position, potentially accelerating its development projects and strengthening its market presence in the biotechnology sector.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for eye diseases. The company is primarily engaged in creating treatments for conditions such as wet age-related macular degeneration and diabetic macular edema, aiming to address significant unmet medical needs in the ophthalmology market.
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
Learn more about OPT stock on TipRanks’ Stock Analysis page.